STING1 and neoplasm: Synthetic agonists for other innate immune-activating moleculeslike the stimulator of interferon genes (STING) are also being developedas tumor vaccines or intratumoral immune activators including ADU-V19(RR–S2 cGAMP)22 and ADU-S100 (MLRRS2 CDA or MIW815).23 ADU-S100 is undergoingphase I or phase II clinical trials (NCT03937141, NCT03172936, andNCT02675439).